Portfolio News

 

   
June 24, 2016
Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement
Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement   --Transaction forms combined NASDAQ-listed biopharmaceutical company, focused on the discovery, development and commercialization of plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME)   --KalVista to become a wholly owned subsidiary of Carbylan, and KalVista shareholders to become majority owners of Carbylan upon the closing ...

Read more

Team - Kate Bingham
January 2015
Entellus Medical - IPO
SV Life Sciences Advisers notes that Entellus Medical successfully listed on NASDAQ on 29 January 2015 The business wire press release is below Nasdaq Welcomes Entellus Medical, Inc. (Nasdaq: ENTL) to The Nasdaq Stock Market NEW YORK, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced that trading of Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company, commenced on The Nasdaq Stock Market on January 29, 2015.

Read more

Team - Paul LaViolette, David Milne
January 2015
Sale of Convergence Pharmaceuticals
SV Life Sciences Fund V notes that Biogen Idec (NASDAQ: BIIB) acquired Convergence from its owners, SV Life Sciences and others, for a possible total of $675m - $200m upfront and $475m of milestone based payments.  Convergence Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for chronic pain.  Biogen Idec Press release   ...

Read more

Team - Kate Bingham
December 2014
Oncoethix Exit
SV Life Sciences Fund V notes that Merck acquired Oncoethix from its owners, SV Life Sciences and others, for an upfront payment of $110m. Additional milestone payments of up to $265m are contingent upon clinical and regulatory events being achieved. Oncoethix is a clinical stage biotechnology company developing innovative cancer drugs. . Merck Press Release ...

Read more

Team - Kate Bingham, Michael Carter
May 2014
Kalvista Pharmaceuticals - Investment
SV Life Sciences Fund IV invested in Kalvista as part of a $5.2m Series A2 extension financing round. Kalvista is a Pharmaceutical and Ophthalmology company developing Plasma Kallikrein inhibitors.   ...

Read more

Team - Kate Bingham, Graham Boulnois
May 2014
Avitide
SV Life Sciences Fund V invested in Avitide as part of a $3.4m Series B financing round. Avitide is a biopharmaceutical company dedicated to the discovery and development of affinity purification products that will improve the fundamental timeframes and economics of commercial bioprocessing.   ...

Read more

Team - Michael Ross
March 31, 2014
Aptiv Exit
SV Life Sciences Fund IV notes that Icon acquired Aptiv from its owners, SV Life Sciences and others for $143.5m. Aptiv is a global development services company focused on enhancing clinical trial decision making and drug and device development through the design, simulation and execution of adaptive clinical trials and a novel statistical sampling approach to risk based monitoring.

Read more

Team - Kate Bingham
January 2014
Thesan Pharmaceticals
SV Life Sciences V invested in Thesan Pharmaceuticals, a dermatology company focused on therapeutics for the treatment of atopic dermatitis and acne, as part of a $49m series B financing round.  ...

Read more

Team - Michael Ross
December 2013
Rempex Pharmacuticals Exit
SV Life Sciences notes that on 04 December 2013 – The Medicines Company (NASDAQ: MDCO) entered in to a definitive agreement to purchase Rempex Pharmaceuticals for an upfront payment price of $140m and has agreed to pay Rempex equity holders milestone payments subsequent to closing. ...

Read more

Team - Michael Ross
November 2013
Sutro Biopharma
SV Life Science Fund V invested in Sutro Biopharma, an on-going development of low cost, high quality rapidly developed protein pharmaceuticals and innovative vaccines, as part of a $26m series D financing round.  ...

Read more

Team - Michael Ross
November 2013
Juvaris - Investment
SV Life Sciences Fund IV invested in Juvaris, developing adjuvanted vaccines for infectious diseases as part of a $300k bridge loan financing round.  ...

Read more

Team - Bruce A Peacock, Michael Ross
November 2013
TopiVert Investment
SV Life Sciences notes that SV Life Science Fund V invested in TopiVert, focused on developing topical medicines for inflammatory diseases of the eye and gut as part of a £1m bridge funding round.   ...

Read more

Team - Kate Bingham, Graham Boulnois, Hamish Cameron, Michael Carter
October 29, 2013
Delenex Therapeutics
SV Life Sciences Advisers notes that Delenex Therapeutics closes CHF 7.3 (USD 8.0) Million Series A3 Financing.   Delenex Therapeutics AG, a biotechnology company developing topical and local treatments for dermatologic diseases using its proprietary PENTRA bodies, today announced the closing of a CHF 7.3 (USD 8.0) Million Series A3 round. All existing venture investors, HBM Ventures, Novo A/s, SV Life Sciences, BioMedinvest and Venture Incubator participated in the round.

Read more

Team - Kate Bingham, Graham Boulnois
September 24, 2013
Ophthotech- IPO
SV Life Sciences Advisers notes that Ophthotech successfully listed on NASDAQ on 25 September 2013 NEW YORK, Sep 24, 2013 (BUSINESS WIRE) -- Ophthotech Corporation today announced the pricing of its initial public offering of 7,600,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Ophthotech.

Read more

Team - David Guyer, Michael Ross

⇧ Back to top